Search results for: Peter A. McSweeney

Items from 1 to 20 out of 27 results

article

Prophylactic corticosteroid use in patients receiving axicabtagene ciloleucel for large B‐cell lymphoma

Olalekan O. Oluwole, Krimo Bouabdallah, Javier Muñoz, Sophie De Guibert, more

British Journal of Haematology > 194 > 4 > 690 - 700

ZUMA‐1 (NCT02348216) examined the safety and efficacy of axicabtagene ciloleucel (axi‐cel), an autologous CD19‐directed chimaeric antigen receptor (CAR)‐T cell therapy, in refractory large B‐cell lymphoma. To reduce treatment‐related toxicity, several exploratory safety management cohorts were added to ZUMA‐1. Specifically, cohort 6 investigated management of cytokine release syndrome (CRS) and neurologic...

article

A Network Approach to Standardization of BMT Pathways

Peter A. McSweeney, Carlos Bachier, Jesus G. Berdeja, Hana Safah, more

Biology of Blood and Marrow Transplantation > 2015 > 21 > 2 Supplement > S359

article

Transplantation for Autoimmune Diseases in North and South America: A Report of the Center for International Blood and Marrow Transplant Research

Marcelo C. Pasquini, Julio Voltarelli, Harold L. Atkins, Nelson Hamerschlak, more

Biology of Blood and Marrow Transplantation > 2012 > 18 > 10 > 1471-1478

Hematopoietic cell transplantation (HCT) is an emerging therapy for patients with severe autoimmune diseases (AID). We report data on 368 patients with AID who underwent HCT in 64 North and South American transplantation centers reported to the Center for International Blood and Marrow Transplant Research between 1996 and 2009. Most of the HCTs involved autologous grafts (n = 339); allogeneic HCT...

article

Cost and Clinical Analysis of Autologous Hematopoietic Stem Cell Mobilization with G-CSF and Plerixafor Compared to G-CSF and Cyclophosphamide

Paul Shaughnessy, Miguel Islas-Ohlmayer, Julie Murphy, Maureen Hougham, more

Biology of Blood and Marrow Transplantation > 2011 > 17 > 5 > 729-736

Plerixafor plus granulocyte-colony stimulating factor (G-CSF) has been shown to mobilize more CD34 ⁺ cells than G-CSF alone for autologous hematopoietic stem cell transplantation (HSCT). However, many centers use chemotherapy followed by G-CSF to mobilize CD34 ⁺ cells prior to HSCT. We performed a retrospective study of patients who participated in the expanded access program (EAP)...

article

Extended Mycophenolate Mofetil and Shortened Cyclosporine Failed to Reduce Graft-versus-Host Disease after Unrelated Hematopoietic Cell Transplantation with Nonmyeloablative Conditioning

Frédéric Baron, Brenda M. Sandmaier, Barry E. Storer, Michael B. Maris, more

Biology of Blood and Marrow Transplantation > 2007 > 13 > 9 > 1041-1048

We previously reported data from 103 patients with hematologic malignancies (median age 54 years) who received peripheral blood stem cell (PBSC) grafts from HLA-matched unrelated donors after nonmyeloablative conditioning and were given postgrafting immunosuppression consisting of mycophenolate mofetil (MMF; administered from day 0 until day +40 with taper through day +96) and cyclosporine (CSP; given...

article

Marking of peripheral T-lymphocytes by retroviral transduction and transplantation of CD34+ cells in a canine X-linked severe combined immunodeficiency model

Steven E. Suter, Terry A. Gouthro, Thomas O’Malley, Brian J. Hartnett, more

Veterinary Immunology and Immunopathology > 2007 > 117 > 3-4 > 183-196

A retrovirus vector containing an enhanced green fluorescent protein complimentary DNA (EGFP cDNA) was used to mark and dynamically follow vector-expressing cells in the peripheral blood of bone marrow transplanted X-linked severe combined immunodeficient dogs. CD34 ⁺ cells isolated from young normal dogs were transduced, using a 2 day protocol, with an amphotropic retroviral vector that expressed...

article

Nonmyeloablative Unrelated Donor Hematopoietic Cell Transplantation to Treat Patients with Poor-Risk, Relapsed, or Refractory Multiple Myeloma

George E. Georges, Michael B. Maris, David G. Maloney, Brenda M. Sandmaier, more

Biology of Blood and Marrow Transplantation > 2007 > 13 > 4 > 423-432

The purpose of this study was to determine long-term outcome of unrelated donor nonmyeloablative hematopoietic cell transplantation (HCT) in patients with poor-risk multiple myeloma. A total of 24 patients were enrolled; 17 patients (71%) had chemotherapy-refractory disease, and 14 (58%) experienced disease relapse or progression after previous autologous transplantation. Thirteen patients underwent...

article

Normal interleukin-7 (IL7) levels and normal IL7 response to CD4 T lymphopenia in patients with multiple sclerosis and systemic sclerosis

Jan Storek, Richard A. Nash, Peter A. McSweeney, Daniel E. Furst, more

Clinical Immunology > 2006 > 121 > 1 > 118-119

article

Unrelated Donor Granulocyte Colony-Stimulating Factor–Mobilized Peripheral Blood Mononuclear Cell Transplantation after Nonmyeloablative Conditioning: The Effect of Postgrafting Mycophenolate Mofetil Dosing

Michael B. Maris, Brenda M. Sandmaier, Barry E. Storer, David G. Maloney, more

Biology of Blood and Marrow Transplantation > 2006 > 12 > 4 > 454-465

We previously reported results in 71 patients with advanced hematologic malignancies given HLA-matched unrelated granulocyte colony-stimulating factor–mobilized peripheral blood mononuclear cell (G-PBMC) grafts after fludarabine 90 mg/m ² , 2 Gy of total body irradiation, and postgrafting mycophenolate mofetil (MMF) 15 mg/kg twice daily and cyclosporine 6.25 mg/kg twice daily orally. Graft...

article

Tacrolimus and Mycophenolate Mofetil after Nonmyeloablative Matched-Sibling Donor Allogeneic Stem-Cell Transplantations Conditioned with Fludarabine and Low-Dose Total Body Irradiation

Yago Nieto, Nigel Patton, Timothy Hawkins, Ruth Spearing, more

Biology of Blood and Marrow Transplantation > 2006 > 12 > 2 > 217-225

We evaluated tacrolimus/mycophenolate mofetil (MMF) for graft-versus-host disease (GVHD) prophylaxis after a nonmyeloablative stem cell transplantation (NST) from a matched sibling donor (MSD). Thirty-two patients (median age, 57 years) with advanced hematologic malignancies, who were poor candidates for a conventional myeloablative transplantation, received fludarabine (30 mg/m ² , day −4...

article

Feasibility of Allogeneic Hematopoietic Stem Cell Transplantation for Autoimmune Disease: Position Statement from a National Institute of Allergy and Infectious Diseases and National Cancer Institute–Sponsored International Workshop, Bethesda, MD, March 12 and 13, 2005

Linda M. Griffith, Steven Z. Pavletic, Alan Tyndall, Christopher N. Bredeson, more

Biology of Blood and Marrow Transplantation > 2005 > 11 > 11 > 862-870

article

Phase I and pharmacokinetic study of docetaxel combined with melphalan and carboplatin, with autologous hematopoietic progenitor cell support, in patients with advanced refractory malignancies

Yago Nieto, Elizabeth J. Shpall, Scott I. Bearman, Peter A. McSweeney, more

Biology of Blood and Marrow Transplantation > 2005 > 11 > 4 > 297-306

The purpose of this study was to define the maximal tolerated dose (MTD), extramedullary toxicities, and pharmacokinetics of docetaxel combined with high-dose melphalan and carboplatin with autologous hematopoietic progenitor cell support. Fifty-nine patients with advanced refractory malignancy (32 breast cancer, 10 non-Hodgkin lymphoma, 6 germ cell tumors, 4 Hodgkin disease, 4 ovarian cancer, 2 sarcoma,...

article

HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with chronic myeloid leukemia

Frédéric Baron, Michael B. Maris, Barry E. Storer, Brenda M. Sandmaier, more

Biology of Blood and Marrow Transplantation > 2005 > 11 > 4 > 272-279

We evaluated 10/10 HLA antigen-matched unrelated hematopoietic cell transplantation (HCT) after nonmyeloablative conditioning with fludarabine 3 × 30 mg/m ² and 2 Gy of total body irradiation as treatment for patients with chronic myeloid leukemia who were ineligible for conventional HCT. Data from 21 consecutive patients in first chronic phase (CP1; n = 12), accelerated phase (AP; n = 5),...

article

Recovery from and consequences of severe iatrogenic lymphopenia (induced to treat autoimmune diseases)

Jan Storek, Zhao Zhao, Eugene Lin, Thomas Berger, more

Clinical Immunology > 2004 > 113 > 3 > 285-298

To ascertain the consequences of severe leukopenia and the tempo of recovery, we studied the immunity of 56 adult patients treated for multiple sclerosis or systemic sclerosis with autologous CD34 cell transplantation using extremely lymphoablative conditioning. NK cell, monocyte, and neutrophil counts recovered to normal by 1 month; dendritic cell and B cell counts by 6 months; and T cell counts...

article

Isolation and characterization of pediatric canine bone marrow CD34 ⁺ cells

Steven E. Suter, Terry A. Gouthro, Peter A. McSweeney, Richard A. Nash, more

Veterinary Immunology and Immunopathology > 2004 > 101 > 1-2 > 31-47

Historically, the dog has been a valuable model for bone marrow transplantation studies, with many of the advances achieved in the dog being directly transferable to human clinical bone marrow transplantation protocols. In addition, dogs are also a source of many well-characterized homologues of human genetic diseases, making them an ideal large animal model in which to evaluate gene therapy protocols...

article

High-dose immunosuppressive therapy and autologous progenitor cell transplantation for systemic sclerosis

Jacob M. van Laar, Peter A. McSweeney

Best Practice & Research Clinical Haematology > 2004 > 17 > 2 > 233-245

High-dose immunosuppressive therapy aimed at immunoablation, given together with autologous stem cell transplantation, has resulted in prolonged (>3 years) improvements of skin thickening and functional ability, together with a stabilization of pulmonary function in two-thirds of treated patients with severe systemic sclerosis. Transplant-related mortality occurred in 17% of the first cohort of...

article

Epstein-Barr virus-associated posttransplantation lymphoproliferative disorder after high-dose immunosuppressive therapy and autologous CD34-selected hematopoietic stem cell transplantation for severe autoimmune diseases

Richard A. Nash, Roger Dansey, Jan Storek, George E. Georges, more

Biology of Blood and Marrow Transplantation > 2003 > 9 > 9 > 583-591

High-dose immunosuppressive therapy followed by autologous hematopoietic stem cell transplantation (HSCT) is currently being evaluated for the control of severe autoimmune diseases. The addition of antithymocyte globulin (ATG) to high-dose chemoradiotherapy in the high-dose immunosuppressive therapy regimen and CD34 selection of the autologous graft may induce a higher degree of immunosuppression...

article

Allografting after nonmyeloablative conditioning as a treatment after a failed conventional hematopoietic cell transplant

Lyle C. Feinstein, Brenda M. Sandmaier, David G. Maloney, Michael B. Maris, more

Biology of Blood and Marrow Transplantation > 2003 > 9 > 4 > 266-272

Outcomes with conventional allogeneic hematopoietic cell transplantation (HCT) after failed HCT are typically poor. To reduce transplantation-related mortality (TRM), 55 patients (median age, 43 years; range, 18-69 years) who had failed conventional autologous (n = 49), allogeneic (n = 4), or syngeneic (n = 2) HCT received human leukocyte antigen-matched related (n = 31) or unrelated (n = 24) donor...

article

Incidence and outcome of bacterial and fungal infections following nonmyeloablative compared with myeloablative allogeneic hematopoietic stem cell transplantation: A matched control study

Christian Junghanss, Kieren A. Marr, Rachel A. Carter, Brenda M. Sandmaier, more

Biology of Blood and Marrow Transplantation > 2002 > 8 > 9 > 512-520

Infections contribute significantly to morbidity and mortality after myeloablative allogeneic hematopoietic stem cell transplantation (HSCT). Whether recipients of nonmyeloablative HSCT have different posttransplantation infection risk was unknown. We therefore analyzed the incidence and risk of bacteremia during the first 100 days and of fungal infection during the first 365 days posttransplantation...

article

Effect of c-mpl ligands after total body irradiation (TBI) with and without allogeneic hematopoietic stem cell transplantation: Low-dose TBI does not prevent sensitization

Richard A. Nash, Alessandra Takatu, Ziding Feng, Sherrill Slichter, more

Biology of Blood and Marrow Transplantation > 2002 > 8 > 7 > 360-367

This study investigates the potential role of the recombinant c-mpl ligands (recombinant human thrombopoietin [rhTPO] and pegylated recombinant human megakaryocyte growth and development factor [PEG-rhMGDF]) on the recovery of platelet counts after TBI with and without allogeneic hematopoietic stem cell transplantation (HSCT) in an established canine model. Initially, 3 cohorts, each with 2 nonirradiated...

Publication date

Set your own date range

Keywords

NONMYELOABLATIVE CONDITIONING (3)
ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (2)
AUTOIMMUNITY (2)
GRAFT-VERSUS-HOST DISEASE (2)
GRAFT-VERSUS-TUMOR EFFECT (2)
HEMATOPOIETIC CELL TRANSPLANTATION (2)
HEMATOPOIETIC STEM CELL TRANSPLANTATION (2)
IMMUNOSUPPRESSION (2)
MULTIPLE SCLEROSIS (2)
MYCOPHENOLATE MOFETIL (2)
NONMYELOABLATIVE TRANSPLANTATION (2)
SYSTEMIC SCLEROSIS (2)
UNRELATED DONOR (2)
AUTOIMMUNE DISEASE (1)
AUTOIMMUNE DISEASES (1)
AUTOLOGOUS TRANSPLANT (1)
AUTOLOGOUS TRANSPLANTATION (1)
AUTOLOGOUS TRANSPLANTS (1)
AXI‐CEL (1)
B LYMPHOCYTES (1)
BONE MARROW TRANSPLANTATION (1)
CANINE MODEL (1)
CD (1)
CD34 SELECTION (1)
CD34+ (1)
CHIMAERIC ANTIGEN RECEPTOR‐T CELL (1)
CHIMERISM (1)
CHRONIC GRAFT-VERSUS-HOST DISEASE (1)
CHRONIC MYELOID LEUKEMIA (1)
CLINICAL TRIAL (1)
CORTICOSTEROIDS (1)
COST ANALYSIS (1)
CYCLOSPORINE (1)
CYTOKINE RELEASE SYNDROME (1)
CYTOKINES (1)
DOCETAXEL (1)
DOG (1)
EBV (1)
EX VIVO CULTURE (1)
EX VIVO GENE THERAPY (1)
GRAFT REJECTION (1)
HEMATOLOGIC MALIGNANCIES (1)
HEMATOLOGIC MALIGNANCY (1)
HEMATOPOIESIS (1)
HEMATOPOIETIC PROGENITOR CELLS (1)
HIGH-DOSE CHEMOTHERAPY (1)
IMMUNODEFICIENCY (1)
LARGE B‐CELL LYMPHOMA (1)
LYMPHOMA (1)
MATCHED SIBLING DONOR (1)
MOBILIZATION (1)
MULTIPLE MYELOMA (1)
NONMYELOABLATIVE (1)
PERIPHERAL BLOOD STEM CELL TRANSPLANTATION (1)
PHARMACODYNAMICS (1)
PHARMACOKINETICS (1)
PHASE I TRIAL (1)
PLERIXAFOR (1)
PROPHYLAXIS (1)
REDUCED-INTENSITY CONDITIONING (1)
RETROVIRAL GENE TRANSFER (1)
SECOND HEMATOPOIETIC CELL ALLOGRAFTS (1)
T LYMPHOCYTES (1)
TACROLIMUS (1)
TRANSPLANT-RELATED TOXICITIES (1)
UNRELATED DONOR ALLOGRAFTING (1)
UNRELATED HEMATOPOIETIC CELL TRANSPLANTATION (1)
more

Data set

Elsevier (24)
Springer (2)
Wiley (1)

INFONA - science communication portal

Search results for: Peter A. McSweeney

Prophylactic corticosteroid use in patients receiving axicabtagene ciloleucel for large B‐cell lymphoma

A Network Approach to Standardization of BMT Pathways

Transplantation for Autoimmune Diseases in North and South America: A Report of the Center for International Blood and Marrow Transplant Research

Cost and Clinical Analysis of Autologous Hematopoietic Stem Cell Mobilization with G-CSF and Plerixafor Compared to G-CSF and Cyclophosphamide

Extended Mycophenolate Mofetil and Shortened Cyclosporine Failed to Reduce Graft-versus-Host Disease after Unrelated Hematopoietic Cell Transplantation with Nonmyeloablative Conditioning

Marking of peripheral T-lymphocytes by retroviral transduction and transplantation of CD34+ cells in a canine X-linked severe combined immunodeficiency model

Nonmyeloablative Unrelated Donor Hematopoietic Cell Transplantation to Treat Patients with Poor-Risk, Relapsed, or Refractory Multiple Myeloma

Normal interleukin-7 (IL7) levels and normal IL7 response to CD4 T lymphopenia in patients with multiple sclerosis and systemic sclerosis

Unrelated Donor Granulocyte Colony-Stimulating Factor–Mobilized Peripheral Blood Mononuclear Cell Transplantation after Nonmyeloablative Conditioning: The Effect of Postgrafting Mycophenolate Mofetil Dosing

Tacrolimus and Mycophenolate Mofetil after Nonmyeloablative Matched-Sibling Donor Allogeneic Stem-Cell Transplantations Conditioned with Fludarabine and Low-Dose Total Body Irradiation

Feasibility of Allogeneic Hematopoietic Stem Cell Transplantation for Autoimmune Disease: Position Statement from a National Institute of Allergy and Infectious Diseases and National Cancer Institute–Sponsored International Workshop, Bethesda, MD, March 12 and 13, 2005

Phase I and pharmacokinetic study of docetaxel combined with melphalan and carboplatin, with autologous hematopoietic progenitor cell support, in patients with advanced refractory malignancies

HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with chronic myeloid leukemia

Recovery from and consequences of severe iatrogenic lymphopenia (induced to treat autoimmune diseases)

Isolation and characterization of pediatric canine bone marrow CD34 ⁺ cells

High-dose immunosuppressive therapy and autologous progenitor cell transplantation for systemic sclerosis

Epstein-Barr virus-associated posttransplantation lymphoproliferative disorder after high-dose immunosuppressive therapy and autologous CD34-selected hematopoietic stem cell transplantation for severe autoimmune diseases

Allografting after nonmyeloablative conditioning as a treatment after a failed conventional hematopoietic cell transplant

Incidence and outcome of bacterial and fungal infections following nonmyeloablative compared with myeloablative allogeneic hematopoietic stem cell transplantation: A matched control study

Effect of c-mpl ligands after total body irradiation (TBI) with and without allogeneic hematopoietic stem cell transplantation: Low-dose TBI does not prevent sensitization

Filter options

Publication date

Keywords

Data set

Journal

INFONA - science communication portal

Search results for: Peter A. McSweeney

Add recipient

Sending message cancelled

Are you sure you want to cancel sending this message?

Send message

Filter options

Publication date

Date range setting

Set the date range to filter the displayed results. You can set a starting date, ending date or both. You can enter the dates manually or choose them from the calendar.

Keywords

Data set

Journal

Reporting an error / abuse

Sending the report failed

Accessibility options